FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
RegulatoryapprovedEnspryngPositive
AI Analysis
Summary
The FDA approved Genentech's Enspryng (satralizumab-mwge) for thyroid eye disease, making it the first and only at-home subcutaneous treatment option for the condition. Enspryng is a first-in-class IL-6R inhibitor.
Outcome Details
FDA approved Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease.
Importance:8/10
Sentiment:
0.80
FDA approvalthyroid eye diseaseIL-6R inhibitorsubcutaneousat-home treatmentfirst-in-classGenentechRoche
Read the original article
Published by Drugs.com New Drug Approvals on October 18, 2026 9:10 PM